Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study [see comment]

Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer (Impact Factor: 4.9). 05/2006; 106(8):1794-803. DOI: 10.1002/cncr.21792
Source: PubMed

ABSTRACT Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters.
A total of 170 patients with MDS were randomized to receive either decitabine at a dose of 15 mg/m2 given intravenously over 3 hours every 8 hours for 3 days (at a dose of 135 mg/m2 per course) and repeated every 6 weeks, or best supportive care. Response was assessed using the International Working Group criteria and required that response criteria be met for at least 8 weeks.
Patients who were treated with decitabine achieved a significantly higher overall response rate (17%), including 9% complete responses, compared with supportive care (0%) (P < .001). An additional 12 patients who were treated with decitabine (13%) achieved hematologic improvement. Responses were durable (median, 10.3 mos) and were associated with transfusion independence. Patients treated with decitabine had a trend toward a longer median time to acute myelogenous leukemia (AML) progression or death compared with patients who received supportive care alone (all patients, 12.1 mos vs. 7.8 mos [P = 0.16]; those with International Prognostic Scoring System intermediate-2/high-risk disease, 12.0 mos vs. 6.8 mos [P = 0.03]; those with de novo disease, 12.6 mos vs. 9.4 mos [P = 0.04]; and treatment-naive patients, 12.3 mos vs. 7.3 mos [P = 0.08]).
Decitabine was found to be clinically effective in the treatment of patients with MDS, provided durable responses, and improved time to AML transformation or death. The duration of decitabine therapy may improve these results further.

Download full-text


Available from: Farhad Ravandi, Aug 24, 2015
1 Follower
  • Source
    • "FDA-approved for myelodysplastic syndromes; incorporated into DNA and blocks DNMT1 [78] Azacytidine (Vidaza Ò ) FDA-approved for myelodysplastic syndromes; incorporated into DNA (and RNA) and blocks DNMT1 [90] SG-110 5-aza-2 0 -deoxycytidine pro-drug [153] Natural Curcumin From curcuma; decreases DNMT1 expression [101] EGCG From green tea; decreases DNMT expression [41] Genistein From soy; decreases DNMT activity and expression [1] Luteolin From parsley, celery; DNMT inhibitor [40] Small molecule Hydralazine Initially used in the treatment of hypertension, DNMT inhibitor [31] HAT Natural Curcumin From curcuma; inhibits HAT (p300) [28] Quercetin From onion, broccoli, berries; sirtuin activator [71] HDAC Benzamides CI-994 (Tacedinaline) Inhibits HDAC1 and 2 [92] MGCD0103 (Mocetinostat) Inhibits HDAC1, 2, 3 and 11 [52] MS-275 (Entinostat) Inhibits class I HDACs [134] Cyclic peptides None in clinical trial Depsipepides FK228 (Romidepsin) FDA-approved; from the bacteria Chromobacterium Violaceum; inhibits class I HDACs [54] Hydroxamates CHR-3996 Inhibits class I HDACs [8] ITF2357 (Givinostat) Inhibits class I and II HDACs [53] JNJ-16241199 (R306465) Inhibits class I HDACs [6] JNJ-26481585 (Quisinostat) Inhibits class I and II HDACs [158] LBH-589 (Panobinostat) Inhibits non-sirtuin HDACs [129] NVP-LAQ824 (Dacinostat) Inhibits class I and II HDACs [21] PCI-24781 (CRA-024781) Inhibits class I and IIb HDACs [20] PXD101 (Belinostat) Inhibits non-sirtuin HDACs [126] SAHA (Vorinostat) FDA-approved, inhibits non-sirtuin HDACs [128] SB939 Inhibits non-sirtuin HDACs [131] Short-chain fatty acids AN-9 (Pivanex, pivaloyloxymethyl butyrate) Inhibits Class I, IIa and IV [38] Butyrate From gut fermentation of dietary fibers; inhibits Class I, IIa and IV [33] Sodium 4-phenylbutyrate Inhibits HDACs [123] VPA Inhibits Class I and IIa [65] Others 3,3-Diindolylmethane Digestive product of indole-3-carbinol found in cruciferous vegetables; inhibits total HDAC activity, downregulation of class I HDACs [13] CUDC-101 Inhibits HDACs [93] Genistein From soy; inhibits non-sirtuin HDACs and increases HAT activity [103] Phenethyl isothiocyanate From cruciferous vegetables; inhibits non-sirtuin HDACs [162] Resveratrol From grape; sirtuin activator [42] Suramin Inhibits SIRT1, 2 and 5 [154] HMT E7438 Inhibits EZH2 [88] DNMT: DNA methyltransferase, EGCG: epigallocatechin gallate, HAT: histone acetyltransferase, HDAC: histone deacetylase, SAHA: suberoylanilide hydroxamic acid, SIRT: sirtuin, VPA: valproic acid. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer remains a major public health problem in our society. The development of potent novel anti-cancer drugs selective for tumor cells is therefore still required. Deregulation of the epigenetic machinery including DNA methylation, histone modifications and non-coding RNAs is a hallmark of cancer, which provides potential new therapeutic targets. Natural products or their derivatives represent a major class of anti-cancer drugs in the arsenal available to the clinician. However, regarding epigenetically active anti-cancer agents for clinics, the oceans represent a largely untapped resource. This review focuses on marine natural compounds with epigenetic activities and their synthetic derivatives displaying anti-cancer properties including largazole, psammaplins, trichostatins and azumamides.
    Cancer Letters 09/2014; 351(2):182–197. DOI:10.1016/j.canlet.2014.06.005 · 5.62 Impact Factor
  • Source
    • "Hypomethylating agents (HMAs), such as azsacitidine (AZA), are considered the standard of care for patients with International Prognostic Scoring System (IPSS) Intermediate- 2 (Int-2) or High-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukaemia (CMML) who are not candidates for allogeneic stem cell transplantation (alloSCT) (Kantarjian et al, 2006; Silverman et al, 2006; Fenaux et al, 2009 "
    British Journal of Haematology 03/2014; 166(2). DOI:10.1111/bjh.12844 · 4.96 Impact Factor
  • Source
    • "TSA is a histone deacetylase inhibitor with a broad spectrum of epigenetic activities; therefore is considered as a potential drug targeting cancer (Drummond et al., 2005) and interferes with the removal of acetyl groups from histones, thus modifying the access of DNA molecules by transcription factors. The 5-AZAC is a hypomethylating agent which inhibits the activity of DNA methyltransferase (Kantarjian et al., 2006). On Day 0, cells from each cell line were seeded into eight wells of a 24-well plate, using the optimum number of cells required to achieve a cell confluency of $70% at the time of harvest (Day 5). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is a heterogeneous and complex disease. Although the use of tumor biomarkers has improved individualized breast cancer care, i.e., assessment of risk, diagnosis, prognosis, and prediction of treatment outcome, new markers are required to further improve patient clinical management. In the present study, a search for novel breast cancer-associated genes was performed by mining the UniGene database for expressed sequence tags (ESTs) originating from human normal breast, breast cancer tissue, or breast cancer cell lines. Two hundred and twenty-eight distinct breast-associated UniGene Clusters (BUC1-228) matched the search criteria. Four BUC ESTs (BUC6, BUC9, BUC10, and BUC11) were subsequently selected for extensive in silico database searches, and in vitro analyses through sequencing and RT-PCR based assays on well-characterized cell lines and tissues of normal and cancerous origin. BUC6, BUC9, BUC10, and BUC11 are clustered on 10p11.21-12.1 and showed no homology to any known RNAs. Overall, expression of the four BUC transcripts was high in normal breast and testis tissue, and in some breast cancers; in contrast, BUC was low in other normal tissues, peripheral blood mononuclear cells (PBMCs), and other cancer cell lines. Results to-date suggest that BUC11 and BUC9 translate to protein and BUC11 cytoplasmic and nuclear protein expression was detected in a large cohort of breast cancer samples using immunohistochemistry. This study demonstrates the discovery and expression analysis of a tissue-restricted novel transcript set which is strongly expressed in breast tissue and their application as clinical cancer biomarkers clearly warrants further investigation. © 2012 Wiley Periodicals, Inc..
    Genes Chromosomes and Cancer 03/2013; 52(3). DOI:10.1002/gcc.22031 · 3.84 Impact Factor
Show more